Compare Harley-Davidson Inc (HOG) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Harley-Davidson Inc vs Zoetis Inc — how do they compare? Harley-Davidson Inc trades at $27.89 (market cap $2.93B), while Zoetis Inc trades at $75.47 (market cap $31.95B). The key difference: Zoetis Inc is far larger — about 10.9× Harley-Davidson Inc's market cap, and Zoetis Inc pays the higher dividend (2.78%). Which is the better fit depends on your goals.
| HOG | ZTS | |
|---|---|---|
Market Cap | $2.93B | $31.95B |
Sector | Consumer Cyclical | Health |
52-Week High | $31.03 | $156.76 |
52-Week Low | $17.19 | $71.91 |
Enterprise Value | $3.32B | $39.24B |
Dividend Yield | 2.64% | 2.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Harley-Davidson (HOG) trades at $28.46, up 7.07% today, showing strong momentum despite mixed earnings performance. The stock exhibits bullish technical signals with valuation metrics appearing attractive (P/E 14.41, P/B 0.96), though revenue has declined from $5.8B in 2022 to $4.5B in 2025. Recent developments include production reshoring of Revolution Max engines and Q2 2026 earnings due July 23, 2026, with expectations of $0.63 EPS.
Outlook remains cautious due to declining revenue trends and margin pressure, offset by cost-cutting initiatives and strategic repositioning. Key risks include competitive pressures and execution challenges, while opportunities lie in operational improvements and potential margin recovery. Analyst consensus is mixed with 65.71% hold rating and $23.40 price target below current levels.
Zoetis (ZTS) trades at $75.33, down 1.61% amid mixed technical signals and ongoing securities litigation. The stock shows strong fundamentals with a 28.03% net margin and 67.75% ROE, supported by consistent revenue growth from $8.1B in 2022 to $9.47B in 2025. Recent earnings beat expectations in Q3 and Q4 2025 but missed in Q1 2026, with Q2 results pending. Analyst consensus remains positive with a $101.43 price target, though technical indicators show neutral momentum near key support at $75.
The outlook for ZTS is cautiously optimistic given robust profitability and analyst support, but significant legal overhangs and recent earnings volatility present near-term risks. Long-term growth in animal health markets offers upside, yet investors should monitor litigation developments and Q2 earnings for directional cues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Harley-Davidson Inc
Harley-Davidson is a global leading manufacturer of heavyweight motorcycles, merchandise, parts, and accessories. It sells custom, cruiser, and touring motorcycles and offers a complete line of Harley-Davidson motorcycle parts, accessories, riding gear, and apparel, as well as merchandise. Harley-Davidson Financial Services provides wholesale financing to dealers and retail financing and insurance brokerage services to customers. Harley has historically captured about half of all heavyweight domestic retail motorcycle registrations, a metric it had ceded in 2020 as it repositioned the business, but a level it is working back toward. In recent years the firm has expanded into the adventure touring market with its Pan America model and into electric with the LiveWire brand.
Read more on HOG →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
